



April 12, 2017

Company name	3 - D	M a t r i x ,	L t d .
A d d r e s s	3-2-4 Kojimachi, Chiyoda-ku, Tokyo		
P r e s i d e n t	Jun Okada		
C o d e N u m b e r	7777		
C o n t a c t	Director	Tomoyuki Arai	
T E L	+81 3 (3511)3440		

Partnership Agreement finalized with PENTAX Europe GmbH regarding sales and marketing of absorbable local hemostat “PuraStat®” in France, the Netherlands, and Portugal

Our consolidated subsidiary in Europe, 3-D Matrix Europe SAS (“3DMEU”), and PENTAX Europe GmbH (“PENTAX”, office located at Julius-Vosseler-Strasse 104, 22527 Hamburg, Germany) have entered into a partnership agreement for the sales and marketing of our absorbable local hemostat “PuraStat®” on April 12th, 2017.

In this agreement, 3DMEU will grant an exclusive sales and marketing license mainly for the GI endoscopy indication to PENTAX in France, the Netherlands, and Portugal. 3DMEU will supply PuraStat®, and PENTAX will market the product through its sales network in these countries.

Rainer Burkard, President EMEA, PENTAX Medical commented, “With the addition of PuraStat® to our ESD accessories portfolio, we are able to provide a comprehensive solution for treatment and therapy, characterized by safety and ease-of-use and supported by the complete hemostatic solution for targeted and delayed bleeding.”

With this agreement, PuraStat® will have presence in several important European markets, including France and the Netherlands. France has a population of 66 million people, average medical expenditure per capita of JPY 552K*1 (Japan: JPY 412K*1) and is one of the largest medical markets in Europe, while the Netherlands has an average medical expenditure per capita of JPY 634K*1 and possesses some of the top medical research facilities in Europe.

3-D Matrix group will continue to develop and strengthen PuraStat®’s sales platform in the EMEA region through its subsidiaries in Europe.

This announcement does not influence the earning forecast of the company for FY2016. We are currently examining the effect on our mid-term plan, announced 14th June 2016, and will make announcements of these results during the coming fiscal year.

ENDS

Reference:

*1: World Health Organization Global Health Expenditure database, Retrieved from
<http://data.worldbank.org/indicator/SH.XPD.PCAP?view=map>